UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December
21, 2015
| mPHASE TECHNOLOGIES, INC. |
| (Exact Name of Registrant as Specified in Charter) |
| New Jersey | 000-24969 | 22-2287503 | ||
| (State or Other Jurisdiction of | (Commission File Number) | (IRS Employer | ||
| Identification No.) | Incorporation) |
| 587 Connecticut Ave., Norwalk, CT 06854-0566 |
| (Address of Principal Executive Offices) (ZIP Code) |
Registrant's telephone number, including area code: (203) 838-2741
Item 8.01 Other Events
On December 19, 2015 mPhase Technologies, Inc. (the “Company”) received a Notice of Allowance of a Patent covering a Drug Delivery System from the United States Patent and Trademark Office.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| mPHASE TECHNOLOGIES | ||
| Date: December 22, 2015 | By: | /s/ Martin S. Smiley |
| Martin S. Smiley | ||
| Executive Vice President, | ||
| Chief Financial Officer and | ||
| General Counsel | ||
3